Korea’s Government-Funded Venture into Oncology
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Address: 15F, Haesung-2-building, Teheran-Ro 508, Gangnam-gu ,Seoul, Republic of Korea 135-725
Tel: +82-2-2185-3800
Web: http://www.merck.co.kr/en/index.html;jsessionid=BD027DF767B36C40BA9C1C74E6E903E9
Merck Republic of Korea, a Republic of Korean subsidiary of Merck KGaA Germany, a global research-driven pharmaceutical company dedicated to putting patients first; Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. Merck Republic of Korea Ltd. was founded in 1989 and established Merck Advanced Technologies Ltd. (MAT) in 2002 to better serve the Republic of Korean display industry. In the same year, an R&D and production center for liquid crystals and a warehouse were opened in Poseung.Earlier in 2009, Merck announced it is investing 14 billion Republic of Korean Won (? 11 million) to establish an Advanced Technology Center in Republic of Korea to improve it’s R&D and manufacturing capacities.
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
